Bristol-Myers bumps off chief scientist in another big shakeup, bringing in Celgene and Novartis execs
Just 2 years after Tom Lynch stepped from the board room to the top scientific position at Bristol-Myers Squibb, he’s out.
The pharma giant reported Wednesday morning that Lynch will leave his post as CSO in four months, moving Celgene R&D exec Rupert Vessey into the top research position after the big merger while recruiting Novartis oncology development head Samit Hirawat for chief medical officer with command of the development group.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.